On August 5, Elanco Animal Health Inc rose 8.52% in pre-market trading, trading at $28.12/share, with turnover of $36,100. The surge was driven by Q2 earnings that broadly exceeded market expectations alongside an upward revision to full-year guidance.

Elanco reported Q2 adjusted EPS of $0.34, beating the consensus estimate of $0.27 by 26% and representing a 30.8% year-over-year increase. Revenue came in at $1.368 billion, surpassing the $1.313 billion estimate and growing 10.5% year-over-year. The company raised its full-year adjusted EPS guidance to $1.10-$1.16, up from $1.03-$1.09, and lifted revenue guidance to $5.09-$5.14 billion from $5.01-$5.09 billion, both above analyst consensus. Q3 guidance of $0.19-$0.22 EPS on revenue of $1.195-$1.220 billion also met or exceeded expectations.

Notably, UBS had previously identified Elanco as the best-positioned name heading into the Q2 print among animal health stocks, a call now validated by the strong results. This marks the third consecutive quarter of earnings beats for the company.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)